Cover Image
市場調查報告書

糖尿病胃輕癱 : 開發中產品分析

Diabetic Gastroparesis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229780
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
糖尿病胃輕癱 : 開發中產品分析 Diabetic Gastroparesis - Pipeline Review, H1 2017
出版日期: 2017年03月22日 內容資訊: 英文 57 Pages
簡介

所謂胃輕癱是糖尿病的長期性併發症之一,會對胃的消化功能帶來不良影響。由於持續性高血糖造成人體各處神經,尤其是迷走神經(消化時控制胃收縮活動的神經)受到侵襲。一旦發病會產生痙攣和腹痛,稍微進食也感到飽脹,噁心·嘔吐,胃逆流,胃灼熱,飽脹感等症狀。同時更可因食慾不振和營養攝取量的減少,導致體重減少和營養失調。

本報告提供全球各國治療糖尿病胃輕癱所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

糖尿病胃輕癱概要

治療藥的開發

  • 糖尿病胃輕癱開發中產品:概要
  • 糖尿病胃輕癱開發中產品:比較分析

企業開發中的的治療藥

大學/機關研究中的治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

糖尿病胃輕癱開發治療藥的企業

  • Cempra Inc
  • Evoke Pharma, Inc.
  • GlaxoSmithKline Plc
  • Motus Therapeutics Inc
  • Shire Plc
  • Theravance Biopharma, Inc.

糖尿病胃輕癱:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

糖尿病胃輕癱治療藥:開發暫停的產品

糖尿病胃輕癱治療藥:開發中止的產品

糖尿病胃輕癱相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9073IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2017, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss of appetite and reduced absorption of nutrients may also be experienced. Gastroparesis can lead to weight loss and malnutrition.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 3, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Gastroparesis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Gastroparesis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Gastroparesis - Overview
  • Diabetic Gastroparesis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Diabetic Gastroparesis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Diabetic Gastroparesis - Companies Involved in Therapeutics Development
    • Cempra Inc
    • Evoke Pharma Inc
    • GlaxoSmithKline Plc
    • Motus Therapeutics Inc
    • Shire Plc
    • Theravance Biopharma Inc
  • Diabetic Gastroparesis - Drug Profiles
    • camicinal - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEM-031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETX-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • metoclopramide hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • prucalopride succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relamorelin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • renzapride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate nNOS for Diabetic Gastroparesis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • velusetrag hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Diabetic Gastroparesis - Dormant Projects
  • Diabetic Gastroparesis - Discontinued Products
  • Diabetic Gastroparesis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 04, 2017: Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial
      • Dec 15, 2016: Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti
      • Dec 06, 2016: Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis
      • Sep 07, 2016: Evoke Pharma Announces Positive Non-Clinical Pre-NDA Meeting with FDA for Gimoti
      • Jul 26, 2016: Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001
      • Jul 18, 2016: Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial
      • Jul 07, 2016: Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement
      • Jun 01, 2016: Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
      • May 24, 2016: Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016
      • May 19, 2016: Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001
      • May 03, 2016: Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001
      • Apr 25, 2016: Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
      • Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
      • Mar 03, 2016: Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts
      • Mar 01, 2016: Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Gastroparesis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Diabetic Gastroparesis - Pipeline by Cempra Inc, H1 2017
  • Diabetic Gastroparesis - Pipeline by Evoke Pharma Inc, H1 2017
  • Diabetic Gastroparesis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Diabetic Gastroparesis - Pipeline by Motus Therapeutics Inc, H1 2017
  • Diabetic Gastroparesis - Pipeline by Shire Plc, H1 2017
  • Diabetic Gastroparesis - Pipeline by Theravance Biopharma Inc, H1 2017
  • Diabetic Gastroparesis - Dormant Projects, H1 2017
  • Diabetic Gastroparesis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Diabetic Gastroparesis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top